The evolving landscape of drug products containing nanomaterials in the United States

Nature Nanotechnology

Volumn 12, Issue 6, 2017, Pages 523-529

  D'Mello, Sheetal R ^a   Cruz, Celia N ^a   Chen, Mei Ling ^a   Kapoor, Mamta ^a   Lee, Sau L ^a   Tyner, Katherine M ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NANOSTRUCTURED MATERIALS; NANOTECHNOLOGY; PARTICLE SIZE ANALYSIS;

AVERAGE PARTICLE SIZE; DRUG EVALUATION; INVESTIGATIONAL NEW DRUGS; LIPOSOMAL FORMULATION; NANOTECHNOLOGY APPLICATIONS; NEW DRUG APPLICATIONS; RELATIVE RATES; US FOOD AND DRUG ADMINISTRATION;

DRUG PRODUCTS;

ANTINEOPLASTIC AGENT; LIPOSOME; NANOMATERIAL; NEW DRUG; DRUG;

ARTICLE; CANCER THERAPY; CHEMICAL COMPOSITION; DRUG FORMULATION; DRUG INDUSTRY; FOOD AND DRUG ADMINISTRATION; HUMAN; MALIGNANT NEOPLASM; NANOTECHNOLOGY; PARTICLE SIZE; PRIORITY JOURNAL; TREND STUDY; UNITED STATES; DRUG APPROVAL; DRUG DESIGN;

DRUG APPROVAL; DRUG DESIGN; HUMANS; LIPOSOMES; NANOSTRUCTURES; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 85018353070     PISSN: 17483387     EISSN: 17483395     Source Type: Journal    
DOI: 10.1038/nnano.2017.67     Document Type: Article

References (61)

1. Devalapally, H., Chakilam, A. & Amiji, M. M. Role of nanotechnology in pharmaceutical product development. J. Pharm. Sci. 96, 2547-2565 (2007).
2. Duncan, R. & Gaspar, R. Nanomedicine(s) under the microscope. Mol. Pharmacol. 8, 2101-2141 (2011).
3. Rizzo, L. Y., Theek, B., Storm, G., Kiessling, F. & Lammers, T. Recent progress in nanomedicine: therapeutic, diagnostic and theranostic applications. Curr. Opin. Biotechnol. 24, 1159-1166 (2013).
4. Thorley, A. J. & Tetley, T. D. New perspectives in nanomedicine. Pharmacol. Ther. 140, 176-185 (2013).
5. US FDA. Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology http://www.fda.gov/RegulatoryInformation/ Guidances/ucm257698.htm (2014).
6. Hamburg, M. A. FDAs approach to regulation of products of nanotechnology. Science 336, 299-300 (2012).
7. Lostritto, R. T., Goei, L. & Silvestri, S. L. Theoretical considerations of drug release from submicron oil in water emulsions. J. Parenter. Sci. Technol. 41, 214-219 (1987).
8. U.S. FDA. Guidance, Compliance, & Regulatory Information http://www.fda. gov/Drugs/GuidanceComplianceRegulatoryInformation/ (2015).
9. Tyner, K. M. et al. Product quality for nanomaterials: current U.S. experience and perspective. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 7, 640-654 (2015).
10. Brown, P. D. & Patel, P. R. Nanomedicine: a pharma perspective. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 7, 125-130 (2015).
11. Poste, G. et al. Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. Can. Res. 42, 1412-1422 (1982).
12. Weissig, V., Pettinger, T. K. & Murdock, N. Nanopharmaceuticals (part 1): products on the market. Int. J. Nanomed. 9, 4357-4373 (2014).
13. Letter, T. M. Griseofulvin: a new formulation and some old concerns. Med. Lett. Drugs Ther. 18, 17-18 (1973).
14. Wu, Y. et al. Core size determination and structural characterization of intravenous iron complexes by cryogenic transmission electron microscopy. Int. J. Pharm. 505, 167-174 (2016).
15. Jahn, M. R., Mrestani, Y., Langguth, P. & Neubert, R. H. CE characterization of potential toxic labile iron in colloidal parenteral iron formulations using off-capillary and on-capillary complexation with EDTA. Electrophoresis 28, 2424-2429 (2007).
16. US FDA. CDER New Drug Review: 2014 Update http://www.fda.gov/ AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ ucm074833.htm (2014).
17. Dickson, M. & Gagnon, J. P. The cost of new drug discovery and development. Discov. Med. 4, 172-179 (2004).
18. Hay, M., Thomas, D. W., Craighead, J. L., Economides, C. & Rosenthal, J. Clinical development success rates for investigational drugs. Nat. Biotechnol. 32, 40-51 (2014).
19. Committee for the Review of the National Nanotechnology Inititative. Preliminary Comments, Review of the National Nanotechnology Initiative (National Academies Press(2001); https://www.nap.edu/read/10216/chapter/1
20. DiMasi, J. A., Hansen, R. W. & Grabowski, H. G. The price of innovation: new estimates of drug development costs. J. Health. Econ. 22, 151-185 (2003).
21. Evens, R. P. in Drug and Biological Development: From Molecule to Product and Beyond (ed. Evens, R. P.) Ch. 1, 5-32 (Springer, 2007).
22. US Congress, Office of Technology Assessment. Government Regulation and Pharmaceutical R and D. 135-168 (US Government Printing Office, 1993).
23. Helmus, M. N. The need for rules and regulations. Nat. Nanotech. 2, 333-334 (2007).
24. US Food and Drug Administration. Bioequivalence Recommendations for Specific Products http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/UCM072872.pdf (2010)
25. Allen, T. M. & Cullis, P. R. Liposomal drug delivery systems: from concept to clinical applications. Adv. Drug Deliv. Rev. 65, 36-48 (2013).
26. Jesorka, A. & Orwar, O. Liposomes: technologies and analytical applications. Annu. Rev. Anal. Chem. 1, 801-832 (2008).
27. Barenholz, Y. Doxil-The first FDA-approved nano-drug: lessons learned. J. Control Rel. 160, 117-134 (2012).
28. Jiang, W., Lionberger, R. & Yu, L. X. In vitro and in vivo characterizations of PEGylated liposomal doxorubicin. Bioanalysis 3, 333-344 (2011).
29. Sercombe, L. et al. Advances and challenges of liposome assisted drug delivery. Front. Pharmacol. 6, 286 (2015).
30. Blanco, E. et al. Nanomedicine in cancer therapy: innovative trends and prospects. Cancer Sci. 102, 1247-1252 (2011).
31. Sumer, B. & Gao, J. Theranostic nanomedicine for cancer. Nanomedicine 3, 137-140 (2008).
32. Davis, M. E., Chen, Z. G. & Shin, D. M. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7, 771-782 (2008).
33. Jain, R. K. & Stylianopoulos, T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 7, 653-664 (2010).
34. Lammers, T., Hennink, W. E. & Storm, G. Tumour-targeted nanomedicines: principles and practice. Br. J. Cancer 99, 392-397 (2008).
35. Bartlett, J. A. et al. Summary report of PQRI workshop on nanomaterial in drug products: current experience and management of potential risks. AAPS J. 17, 44-64 (2015).
36. Hall, J. B., Dobrovolskaia, M. A., Patri, A. K. & McNeil, S. E. Characterization of nanoparticles for therapeutics. Nanomedicine 2, 789-803 (2007).
37. Tyner, K. & Sadrieh, N. Considerations when submitting nanotherapeutics to FDA/CDER for regulatory review. Methods Mol. Biol. 697, 17-31 (2011).
38. Kobayashi, H. & Brechbiel, M. W. Dendrimer-based macromolecular MRI contrast agents: characteristics and application. Mol. Imaging 2, 1-10 (2003).
39. De Jong, W. H. et al. Particle size-dependent organ distribution of gold nanoparticles after intravenous administration. Biomaterials 29, 1912-1919 (2008).
40. Alexis, F., Pridgen, E., Molnar, L. K. & Farokhzad, O. C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 5, 505-515 (2008).
41. Gmoshinski, I. V. et al. Nanomaterials and nanotechnologies: methods of analysis and control. Russ. Chem. Rev. 82, 48 (2013).
42. Linkov, P., Artemyev, M., Efimov, A. E. & Nabiev, I. Comparative advantages and limitations of the basic metrology methods applied to the characterization of nanomaterials. Nanoscale 5, 8781-8798 (2013).
43. Powers, K. W. et al. Research strategies for safety evaluation of nanomaterials. Part VI. Characterization of nanoscale particles for toxicological evaluation. Toxicol. Sci. 90, 296-303 (2006).
44. Powers, K. W., Palazuelos, M., Moudgil, B. M. & Roberts, S. M. Characterization of the size, shape, and state of dispersion of nanoparticles for toxicological studies. Nanotoxicology 1, 42-51 (2007).
45. Warheit, D. B. How meaningful are the results of nanotoxicity studies in the absence of adequate material characterization? Toxicol. Sci. 101, 183-185 (2008).
46. Bhattacharjee, S. DLS and zeta potential-what they are and what they are not? J. Control Rel. 235, 337-351 (2016).
47. Anderson, W., Kozak, D., Coleman, V. A., Jamting, A. K. & Trau, M. A comparative study of submicron particle sizing platforms: accuracy, precision and resolution analysis of polydisperse particle size distributions. J. Colloid Interface Sci. 405, 322-330 (2013).
48. Boverhof, D. R. & David, R. M. Nanomaterial characterization: considerations and needs for hazard assessment and safety evaluation. Anal. Bioanal. Chem. 396, 953-961 (2009).
49. Lin, P.-C., Lin, S., Wang, P. C. & Sridhar, R. Techniques for physicochemical characterization of nanomaterials. Biotechnol. Adv. 32, 711-726 (2014).
50. McNeil, S. E. (ed.) Characterization of Nanoparticles Intended for Drug Delivery Vol. 697 (Springer, 2011).
51. Sapsford, K. E., Tyner, K. M., Dair, B. J., Deschamps, J. R. & Medintz, I. L. Analyzing nanomaterial bioconjugates: a review of current and emerging purification and characterization techniques. Anal. Chem. 83, 4453-4488 (2011).
52. Grau, M. J., Kayser, O. & Muller, R. H. Nanosuspensions of poorly soluble drugs -reproducibility of small scale production. Int. J. Pharm. 196, 155-159 (2000).
53. Muller, R. H., Jacobs, C. & Kayser, O. Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv. Drug Deliv. Rev. 47, 3-19 (2001).
54. European Commission. Recommendation on the Definition of Nanomaterial (European Commission, 2011).
55. Health Canada. Policy Statement on Health Canadas Working Definition for Nanomaterial (Health Canada, 2011).
56. ISO. International Organization for Standardization/Technical Specification, Nanotechnologies-Vocabulary-Part 1: Core terms 2010, ISO/TS 80004-1: 2010 (ISO 2010)
57. NSTC/CoT/NSET. National Nanotechnology Initiative Strategic Plan http:// www.nano.gov/sites/default/files/pub-resource/2014-nni
58. Bancos, S., Stevens, D. L. & Tyner, K. M. Effect of silica and gold nanoparticles on macrophage proliferation, activation markers, cytokine production, and phagocytosis in vitro. Int. J. Nanomed. 10, 183-206 (2015).
59. Bancos, S., Tsai, D.-H., Hackley, V., Weaver, J. L. & Tyner, K. M. Evaluation of viability and proliferation profiles on macrophages treated with silica nanoparticles in vitro via plate-based, flow cytometry, and Coulter counter assays. ISRN Nanotechnol. 2012, 454072 (2012).
60. Keene, A. M. et al. Tissue and cellular distribution of gold nanoparticles varies based on aggregation/agglomeration status. Nanomedicine 7, 199-209 (2012).
61. Keene, A. M. & Tyner, K. M. Analytical characterization of gold nanoparticle primary particles, aggregates, agglomerates, and agglomerated aggregates. J. Nanopart. Res. 13, 3465-3481 (2011).